Drug Profile
TRK 001
Alternative Names: Autologous T regulatory cell therapy - TRACT Therapeutics; TRK-001Latest Information Update: 21 Sep 2023
Price :
$50
*
At a glance
- Originator Tract Therapeutics
- Developer Northwestern University; Tract Therapeutics
- Class T lymphocyte cell therapies
- Mechanism of Action Regulatory T-lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Renal transplant rejection
- Preclinical Crohn's disease
- Discontinued Autoimmune hepatitis; Liver transplant rejection
Most Recent Events
- 21 Sep 2023 Phase I development is ongoing in Renal transplant rejection (Prevention) in USA (IV) (Tract Therapeutics pipeline, September 2023)
- 21 Sep 2023 Preclinical development is ongoing in Crohn's disease in USA (IV) (Tract Therapeutics pipeline, September 2023)
- 11 Feb 2022 Discontinued - Phase-I for Autoimmune hepatitis in USA (IV) (Tract Therapeutics pipeline, February 2022)